Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and...

Full description

Bibliographic Details
Main Authors: Sybil Tasker, Anna Wight O’Rourke, Anvar Suyundikov, Peta-Gay Jackson Booth, Stephan Bart, Vyjayanthi Krishnan, Jianfeng Zhang, Katie J. Anderson, Bertrand Georges, M. Scot Roberts
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Vaccines
Subjects:
influenza vaccine
intranasal vaccine
adenovirus vector
NasoVAX
mucosal immunity
pre-existing immunity
Online Access:https://www.mdpi.com/2076-393X/9/3/224

Internet

https://www.mdpi.com/2076-393X/9/3/224

Similar Items